t
Arecor Therapeutics plc announced on 23 April 2024 that Susan Lowther will step down from her roles as Chief Financial Officer, Company Secretary, and Board Director. Her last day with the company is expected to be 22 July. She has contributed to Arecor for the past five years.
| Date | 23 Apr 2024 |
| Time | 07:00:10 |
| Category | Board changes |
| ID | 5889L |
Arecor Therapeutics plc
("Arecor" or the "Company")
BOARD CHANGE
ARECOR ANNOUNCES SUSAN LOWTHER TO STEP DOWN AS CHIEF FINANCIAL OFFICER
Cambridge, UK, 23 April 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announced that Susan Lowther has decided to step down from her role as Chief Financial Officer, Company Secretary and as a Board Director, to pursue new opportunities.
A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.
Sarah Howell, Chief Executive Officer of Arecor, said: "On behalf of the Board and all at Arecor, I want to thank Susan for her contributions over the past five years, in our transition to a public company and growth as a business. We wish her every success in her future plans."
Susan Lowther, Chief Financial Officer of Arecor, said: "I am proud to have been Arecor's first Chief Financial Officer and of our achievements as a business, and believe the Company is well placed for further growth. I will watch the future progress with interest."
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG Partners LLP (Financial Advisor) |
|
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
|
|
ICR Consilium |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com